NCT06414902

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

Detailed description

Primary Objectives * Evaluate the ability of 18F-FAraG PET imaging to detect tumors in participants with esophageal cancer; * Evaluate 18F-FAraG PET as a predictor of pathologic complete response Secondary Objectives * Evaluate the correlation of 18F-FAraG PET with clinical characteristics * Evaluate the correlation of 18F-FAraG PET with scRNA-seq data * Evaluate tissue and blood biomarkers as predictors of treatment response and disease recurrence * Evaluate functional imaging with 18F-FAraG PET and tissue and blood biomarkers as predictors of overall survival and disease-free survival * Compare 18F-FAraG PET SUV update to the change in standard 18FDG-PET SUV parameters before and after chemoradiation.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	ArabinoFuranosylGuanine [18F]F-AraG	Given by IV

Timeline

• Start date: 2024-09-04
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2024-05-16
• Last updated: 2025-11-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study